All Title Author
Keywords Abstract

Publish in OALib Journal
ISSN: 2333-9721
APC: Only $99

ViewsDownloads

Febuxostat: Successful Desensitization Protocol

DOI: 10.4236/oalib.1108481, PP. 1-5

Subject Areas: Allergy & Clinical Immunology

Keywords: Febuxostat, Drug Allergy, Hypersensitivity, Desensitization Protocol, Allergy

Full-Text   Cite this paper   Add to My Lib

Abstract

Hyperuricemia is defined as the increase in uric acid when it exceeds its solubility limit, about 6.8 mg/dl. Persistent hyperuricemia causes diseases such as gouty arthritis, arthropathy, urolithiasis, and nephropathy. We present the clinical case of a 46-year-old patient with gout and persistent hyperuricemia; he presented cutaneous hypersensitivity to allopurinol and febuxostat and, for this reason, the patient stopped the treatment. After undergoing a 5-day new febuxostat desensitization protocol, he tolerated the drug without adverse effects. This case report highlights the importance of allergy desensitization if there’s no other therapeutic option in patients with hypersensitivity to allopurinol and febuxostat.

Cite this paper

Alonso-Bello, C. D. , Matías-Carmona, M. , Castaneda-ávila, V. I. , Aranda-Cano, E. and Castrejón-Vázquez, M. I. (2022). Febuxostat: Successful Desensitization Protocol. Open Access Library Journal, 9, e8481. doi: http://dx.doi.org/10.4236/oalib.1108481.

References

[1]  Becker, M.A., Schumacher, H.R., Wortmann, R.L., MacDonald, P.A., Eustace, D., Streit, J., et al. (2005) Febuxostat Compared with Allopurinol in Patients with Hyperuricemia and Gout. The New England Journal of Medicine, 353, 2450-2461. https://doi.org/10.1056/NEJMoa050373
[2]  Stamp, L.K., Day, R.O. and Yun, J. (2016) Allopurinol Hypersensitivity: Investigating the Cause and Minimizing the Risk. Nature Reviews Rheumatology, 12, 235-242. https://doi.org/10.1038/nrrheum.2015.132
[3]  Lin, C.W., Huang, W.L., Chao, P.H., Chen, W.W. and Hsiao, F.Y. (2019) Risk of Cutaneous Adverse Reactions Associated with Allopurinol or Febuxostat in Real-World Patients: A Nationwide Study. International Journal of Clinical Practice, 73, e13316. https://doi.org/10.1111/ijcp.13316
[4]  Jordan, A. and Gresser, U. (2018) Side Effects and Interactions of Xanthine Oxidase Inhibitor Febuxostat. Pharmaceuticals (Basel), 11, 51. https://doi.org/10.3390/ph11020051
[5]  Chohan, S. (2011) Safety and Efficacy of Febuxostat Treatment in Subjects with Gout and Severe Alopurinol Adverse Reactions. The Journal of Rheumatology, 38, 1957-1959. https://doi.org/10.3899/jrheum.110092
[6]  Di Paolo, C., Minetti, S., Mineni, M., Inverardi, S., Rizzini, F.L., Cinquini, M., et al. (2015) Desensitization to Febuxostat: Report of Two Cases. The Journal of Allergy and Clinical Immunology: In Practice, 3, 633-636. https://doi.org/10.1016/j.jaip.2015.01.022
[7]  Sulaiman, N., Othman, Z.A., Shahril, N.S., Rashid, A.M., Faeez, M.D. and Noh, M. (2017) Successful Febuxostat Desensitization in a Patient with Febuxostat Hypersensitivity: A Malaysian Experience. SAGE Open Medical Case Reports, 5, 2050313X17749080. https://doi.org/10.1177/2050313X17749080
[8]  Yu, K.H., Lai, J.H., Hsu, P.M., Chen, D.Y., Chen, C.J. and Lin, H.Y. (2016) Safety and Efficacy of Oral Febuxostat for Treatment of HLA-B*5801-Negative Gout: A Randomized, Open-Label, Multicentre, Allopurinol-Controlled Study. Scandinavian Journal of Rheumatology, 45, 304-311. https://doi.org/10.3109/03009742.2015.1099729
[9]  Yeon-Hau, H.L. and Logan, J.L. (2017) Cross-Reactions between Allopurinol and Febuxostat. American Journal of Medicine, 130, e67-e68. https://doi.org/10.1016/j.amjmed.2016.08.042

Full-Text


comments powered by Disqus

Contact Us

service@oalib.com

QQ:3279437679

WhatsApp +8615387084133

WeChat 1538708413